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Certain endoplasmic reticulum (ER)-associated degradation (ERAD) substrates with transmembrane domains are segre-
gated from other ER proteins and sorted into a juxtanuclear subcompartment, known as the ER quality control compart-
ment. Bap31 is an ER protein with three transmembrane domains, and it is assumed to be a cargo receptor for ER export
of some transmembrane proteins, especially those prone to ERAD. Here, we show that Bap31 is a component of the ER
quality control compartment and that it moves between the peripheral ER and a juxtanuclear ER or ER-related compart-
ment distinct from the conventional ER–Golgi intermediate compartment. The third and second transmembrane domains
of Bap31 are principally responsible for the movement to and recycling from the juxtanuclear region, respectively. This
cycling was blocked by depolymerization of microtubules and disruption of dynein–dynactin function. Overexpression
of Sar1p and Arf1 mutants affected Bap31 cycling, suggesting that this cycling pathway is related to the conventional
vesicular transport pathways.
INTRODUCTION
The endoplasmic reticulum (ER) exhibits a reticular tubular
network that extends from the nucleus to the cell periphery
along microtubule tracks. It performs a variety of functions,
including the synthesis, posttranslational modifications,
quality control, and export of secretory and membrane pro-
teins; the synthesis of lipids; stress response; Ca2 storage;
and apoptosis. Most, if not all, of these functions are man-
aged by subdomains, such as the rough and smooth ER and
transitional ER sites. Each subdomain contains a unique set
of proteins that are responsible for its function and organi-
zation. ER subdomains are relatively stable, but they can be
transformed into alternative structures in response to cellu-
lar conditions (for review, see Voeltz et al., 2002; Levine and
Rabouille, 2005; Borgese et al., 2006;Vedrenne and Hauri,
2006).
Several studies showed the presence of a specialized ER
subdomain that is related to ER-associated degradation
(ERAD). ERAD is part of a quality control system that en-
sures the delivery of only correctly folded or assembled
secretory and membrane proteins to their final destinations.
Newly synthesized proteins that fail to fold or assemble
correctly are retained in the ER, retrotranslocated to the
cytosol, and degraded by the ubiquitin–proteasome system
(for review, see Ellgaard and Helenius, 2003; Meusser et al.,
2005; Ro¨misch, 2005). Studies using mammalian cells dem-
onstrated that transmembrane ERAD substrates are segre-
gated into “ER quality control compartments,” which be-
come discernible at the juxtanuclear region upon inhibition
of ERAD by proteasome inhibitors (Kamhi-Nesher et al.,
2001; Spiliotis et al., 2002). In Saccharomyces cerevisiae, ectopi-
cally expressed cystic fibrosis transmembrane conductance
regulator (CFTR) is segregated from other ER proteins and
accumulates in ER-associated compartments (Kiser et al.,
2001; Zhang et al., 2001; Huyer et al., 2004). Degradation of
CFTR in yeast is independent of ER-to-Golgi traffic, but it is
dependent on the function of Sar1p/COPII (Fu and Sztul,
2003), which are components of COPII-coated vesicles in-
volved in ER export (Bonifacino and Glick, 2004; Lee et al.,
2004).
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Bap31 is an integral ER membrane protein with three
putative transmembrane domains (TMDs) and a dilysine
motif at its C terminus (Kim et al., 1994), the latter of which
is known to be able to act as a retrieval signal from post-ER
compartments via COPI-coated vesicles (Cosson and Letourneur,
1994). Bap31 and its homologue Bap29 were originally dis-
covered as B cell receptor-associated proteins (Kim et al.,
1994). Although solid evidence demonstrated that Bap31 is
involved in apoptosis (Breckenridge et al., 2003), accumulat-
ing evidence suggest that Bap31 in healthy cells functions as
a cargo receptor for ER export of transmembrane proteins,
such as cellubrevin, class I major histocompatibility complex
(MHC) molecules, CFTR, membrane-bound immunoglobu-
lin (Ig)G, tetraspanins, cytochrome P450 2C2, and the leuko-
cyte integrin CD11b/CD18, some of which are well-known
ERAD substrates (Annaert et al., 1997; Spiliotis et al., 2000;
Lambert et al., 2001; Schamel et al., 2003; Paquet et al., 2004; Zen
et al., 2004; Stojanovic et al., 2005; Ladasky et al., 2006; Szczesna-
Skorupa and Kemper, 2006).
In the present study, we show that Bap31 is a component
of the ER quality control compartment and that it cycles
between the peripheral ER and a juxtanuclear ER or an
ER-related compartment along microtubule tracks.
MATERIALS AND METHODS
Antibodies
Monoclonal antibodies against prolyl-4-hydroxylase -subunit, sarco(endo)plasmic
reticulum Ca2 ATPase (SERCA2), KDEL (BiP), and multiubiquitin were
purchased from Daiichi Fine Chemical (Tokyo, Japan), Calbiochem (San
Diego, CA), Nventa Biopharmaceuticals (San Diego, CA), and Medical and
Biological Laboratories (Nagoya, Aichi, Japan), respectively. Polyclonal anti-
bodies against Sec61 and Derlin-1 were obtained from Upstate Biotechnol-
ogy (Lake Placid, NY) and Sigma-Aldrich (St. Louis, MO), respectively. To
raise a polyclonal antibody against Bap31, a His6-tagged C-terminal region of
human Bap31 (amino acids 137-246) was expressed in Escherichia coli cells,
purified, and used as an antigen. The rabbit polyclonal antibody against
Bap31 was isolated by affinity chromatography on antigen-coupled beads.
The sources of other antibodies were described previously (Hirose et al., 2004;
Wakana et al., 2005; Arasaki et al., 2006).
Cell Culture
COS-7 and 293T cells were grown in DMEM supplemented with 50 IU/ml
penicillin, 50 g/ml streptomycin, and 10% fetal calf serum. HeLa cells were
cultured in Eagle’s minimal essential medium supplemented with the same
materials. Establishment of stable tetracycline (Tet)-on HeLa cells was per-
formed as described previously (Hirose et al., 2004; Nakajima et al., 2004). To
express Bap31-monomeric red fluorescent protein (mRFP), Tet-on HeLa cells
were incubated with 1 g/ml doxycycline for 48 h.
Treatment of Cells with Chemical Reagents
H89 was obtained from D. Western Therapeutics Institute (Nagoya, Aichi,
Japan). Brefeldin A (BFA) and nocodazole (Noc) were purchased from Sigma-
Aldrich. For H89 experiments, cells were treated with 50 M H89 for 15 min
unless otherwise stated. To test the reversibility of the H89 effect, H89 was
washed out, and the cells were incubated with medium containing 20 g/ml
cycloheximide for 3 h. In the BFA/washout experiments, cells were first
incubated with 10 M BFA for 30 min, washed to remove BFA, and then
incubated with medium containing 20 g/ml cycloheximide. Fetal calf serum
was omitted during incubation of cells with chemical reagents including
lactacystin. To depolymerize microtubules, Noc was used at a concentration
of 5 g/ml.
Immunoprecipitation
293T cells coexpressing FLAG-tagged valosin-containing protein (VCP) and
hemagglutinin (HA)-tagged Bap31 or reticulon 3 were lysed in buffer consist-
ing of 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1 mM dithio-
threitol, 1% Nonidet P-40, 0.1% sodium deoxycholate, 1 g/ml leupeptin, 2
M pepstatin A, 2 g/ml aprotinin, and 1 mM phenylmethylsulfonyl fluo-
ride, and then they were centrifuged at 17,000  g for 10 min. The superna-
tants were immunoprecipitated with a monoclonal antibody (mAb) against
FLAG, and the precipitated proteins were analyzed by immunoblotting with
a mAb against FLAG and a polyclonal antibody against HA or Bap31.
Immunofluorescence Microscopy
For immunofluorescence microscopy, cells were fixed with 4% paraformal-
dehyde for 20 min at room temperature and observed with a Fluoview 300
laser scanning microscope (Olympus, Tokyo, Japan), as described previously
(Tagaya et al., 1996).
Live Cell Imaging
To transiently express N-acetylglucosaminyl transferase I-green fluorescent
protein (NAGFP) and Bap31-mRFP, Tet-on HeLa cells were transfected with
the corresponding plasmids and incubated with 1 g/ml doxycycline for
24 h. Live cell images were acquired continuously with time intervals between
frames of 10 s by using a fluorescence imaging system (Till Photonics, Gra¨felfing,
Germany).
Immunoelectron Microscopic Analysis
Localization of Bap31 was analyzed by immunoelectron microscopy by using
a pre-embedding gold enhancement method. H89-treated HeLa cells were
fixed in 4% paraformaldehyde in 0.1 M sodium phosphate buffer, pH 7.4, for
2 h, incubated in 0.1 M sodium phosphate buffer containing 0.25% saponin for
30 min, and then in 0.1 M sodium phosphate buffer containing 0.005%
saponin, 10% bovine serum albumin, 10% normal goat serum, and 0.1% cold
water fish skin gelatin (blocking solution) for 30 min. The cells were exposed
to an anti-Bap31 in blocking solution overnight, and then they were incubated
with the Fab’ fragment of a goat anti-mouse IgG conjugated to colloidal gold
(1.4 nm in diameter) in blocking solution for 2 h. The cells were fixed with 1%
glutaraldehyde in 0.1 M sodium phosphate buffer for 10 min. The gold
labeling was intensified with a gold enhancement kit (GoldEnhance-EM;
Nanoprobes, Stony Brook, NY) for 3 min according to the manufacturer’s
protocol. After washing, the cells were postfixed in 0.1 M sodium phosphate
buffer containing 1% OsO4 and 1.5% potassium ferrocyanide for 60 min,
dehydrated in a series of graded ethanol solution, and embedded in epoxy
resin. Ultrathin sections were cut horizontally to the cell layer and observed
under a Hitachi H7600 electron microscope.
Fluorescence Loss in Photobleaching
The stable cell lines expressing green fluorescent protein (GFP)-fused proteins
were subjected to two bleach cycles. Each cycle consisted of 64 bleaching
scans at high zoom with high laser intensity (488-nm laser) followed by one
imaging scan at low zoom with low laser intensity. The duration of each cycle
was 1 min 50 s. Last imaging scan was performed at 1 min 10 s after the
second bleach cycle. The total elapsed time was 4 min 50 s. Photobleaching
experiments were conducted with a TCS SP2 AOBS laser scanning micro-
scope (Leica Microsystems, Wetzlar, Germany).
Plasmid Construction and Transfection
The cDNAs encoding full-length Bap31 and full-length Bap29 were inserted
into pTRE (Clontech, Mountain View, CA) together with the cDNA of mRFP
(a gift from Dr. R. Y. Tsien) (Campbell et al., 2002) so as to express proteins
with the C-terminal mRFP in Tet-on HeLa cells in the presence of doxycycline.
The cDNAs encoding chimeras between Bap31 and Bap29 were generated by
overlap extension polymerase chain reaction (PCR) and inserted into pTRE
together with the cDNA of mRFP. The plasmids for FLAG-dynamitin, FLAG-
Sar1p mutants, and HA-reticulon 3 were constructed as described previously
(Hirose et al., 2004; Shimoi et al., 2005; Wakana et al., 2005). The cDNA
encoding Arf1[Q71L] was inserted into pEGFP-N1 (Clontech) and pcDNA3-
based plasmid encoding mRFP to express proteins with the C-terminal GFP
and mRFP, respectively. The plasmids for NAGFP, GFP-CFTRF508, and
GFP-galactosyltransferase were kind gifts from Drs. R. Pepperkok, R. R.
Kopito, and J. Lippincott-Schwartz, respectively. The plasmids for FLAG-VCP
wild-type (WT) and FLAG-VCP K524M were prepared in this laboratory
(Nagahama et al., 2003). Transfection was carried out using Lipofectamine
Plus (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol.
Unless otherwise stated, transfected cells were incubated for 18 h and used for
analysis.
RESULTS
Bap31 Is a Component of the ER Quality Control
Compartment
Although Bap31 exhibited a typical reticular ER pattern in
most COS-7 cells (Figure 1A, left), it was found to accumu-
late at the juxtanuclear region in a few percent of cells
(Figure 1A, right, arrows). This juxtanuclear Bap31 localiza-
tion was reminiscent of the ER quality control compartment,
which becomes discernible at the juxtanuclear region upon
inhibition of ERAD by proteasome inhibitors (Kamhi-
Nesher et al., 2001; Spiliotis et al., 2002). To examine whether
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Bap31 is present in the ER quality control compartment, the
distribution of Bap31 was determined after incubation of
cells with a proteasome inhibitor, lactacystin, for 5 h. As
shown in Figure 1B, Bap31 (top right), but not other ER
proteins (BiP and calnexin, middle row), accumulated at the
juxtanuclear region in 60–70% of lactacystin-treated cells. A
similar result was obtained when another proteasome inhib-
itor, MG132, was used (bottom row). To demonstrate that
Bap31 indeed accumulates in the quality control compart-
ment, cells expressing an ERAD substrate, GFP-CFTRF508,
were treated with MG132, and the distribution of Bap31 was
compared with that of the accumulated ERAD substrate. As
shown in Figure 1C, Bap31 was colocalized with GFP-
CFTRF508 at the juxtanuclear region in MG132-treated
cells. These results suggest that Bap31 is a component of the
ER quality control compartment. To verify that the region
where Bap31 accumulated does not correspond to the Golgi
apparatus or the ER–Golgi intermediate compartment
(ERGIC), we examined the effects of Golgi-disrupting re-
agents BFA and Noc on Bap31 localization in lactacystin-
treated cells. Previous studies showed that the quality con-
trol compartment is insensitive to BFA, but sensitive to Noc
(Kamhi-Nesher et al., 2001; Spiliotis et al., 2002). As shown in
Figure 1D, the accumulated Bap31 in lactacystin-treated cells
was redistributed by Noc, but not by BFA. To compare the
distribution of Bap31 with that of an ERGIC marker, ERGIC-
53, we used HeLa cells because our anti-ERGIC-53 antibody
does not cross-react with simian ERGIC-53. As shown in
Figure 1E, juxtanuclear ERGIC-53–positive structures were
substantially disrupted by BFA treatment, whereas Bap31
accumulation was not. These results suggest that the area
where Bap31 accumulated upon proteasome inhibitor treat-
ment is different from the Golgi or an intermediate compart-
ment containing ERGIC-53.
As intact microtubules are required for maintaining jux-
tanuclear accumulation of Bap31 in lactacystin-treated cells
(Figure 1D, right), we asked whether the microtubule mi-
nus-end–directed motor dynein-dynactin is involved in
Bap31 redistribution. We overexpressed dynamitin, which is
known to disrupt the function of the minus-end–directed
motor dynein-dynactin (Burkhardt et al., 1997), in HeLa
cells, and then the cells were incubated with lactacystin for
6 h. When dynamitin was overexpressed, the number of cells
exhibiting the juxtanuclear accumulation of Bap31 was de-
creased by approximately threefold. Figure 1F shows typical
distribution patterns of Bap31 in lactacystin-treated cells
without (left) and with dynamitin overexpression (middle).
Quality Control Compartments Contain Components of
the Retrotranslocation Machinery
ERAD substrates are retrotranslocated from the ER through
a retrotranslocation channel, ubiquitinated, and degraded
by the proteasome system (for review, see Ellgaard and
Helenius, 2003; Meusser et al., 2005; Ro¨misch, 2005). If jux-
tanuclear accumulation of Bap31 indeed occurs as a conse-
quence of inhibition of ERAD, blocking of retrotransloca-
tion, as well as inhibition of proteasomal activity by
chemicals, must induce juxtanuclear accumulation of Bap31.
To test this idea, we overexpressed a VCP mutant in which
Lys-524 in D2 domain was replaced by Met. VCP is an
ATPase that mediates retrotranslocation of ERAD substrates
(Ye et al., 2001), and this type of mutants can exert a domi-
Figure 1. Bap31 is a component of ER quality
control compartments. (A) Localization of
Bap31 in intact COS-7 cells. Arrows indicate
the prominent juxtanuclear accumulation of
Bap31. (B) COS-7 cells were treated with di-
methyl sulfoxide or 25 M lactacystin for 5 h
(top and second rows) or with 5 M MG132
for 16 h (bottom row), and stained for Bap31,
BiP, or calnexin. (C) COS-7 cells expressing
GFP-CFTRF508 were incubated with 5 M
MG132 for 8 h, and then they were stained for
Bap31. (D and E) COS-7 cells (D) or HeLa cells
(E) were incubated with 10 M lactacystin for
6 h (Lactacystin), for 5.5 h and then plus 10 M
BFA for 0.5 h (Lactacystin3BFA), or for 3 h and
then plus 5g/ml Noc for 3 h (Lactacystin3Noc),
and stained for Bap31 (D) or double stained for
Bap31 and ERGIC-53 (E). (F) Control COS-7 cells
(left) or cells expressing FLAG-dynamitin
(middle and right) were incubated with lacta-
cystin for 6 h, and stained for Bap31 (left) or
double stained for Bap31 (middle) and FLAG
(right). Bars, 10 m.
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nant-negative effect on retrotranslocation (Ye et al., 2003).
When FLAG-VCP K524M was expressed in COS-7 cells,
Bap31 as well as the expressed VCP mutant accumulated at
the juxtanuclear region (Figure 2A, second row). Polyubiq-
uitin also accumulated at the same area (third row). In
contrast, no prominent accumulation of Bap31 was observed
when FLAG-VCP WT was expressed (top row). Although an
ER marker, SERCA2, also exhibited some concentration in
the vicinity of the nucleus (fourth row), perhaps due to a
consequence of the formation of large vacuoles in cells
(Hirabayashi et al., 2001), the accumulation of Bap31 at the
juxtanuclear region was much more conspicuous compared
with SERCA2, and very faint reticular staining was observed
for Bap31 (second row). These results confirm that redistri-
bution of Bap31 to the juxtanuclear region is a consequence
of inhibition of ERAD and that Bap31 is a component of the
ER quality control compartment. Notably, Derlin-1 accumu-
lated at the juxtanuclear region upon expression of the VCP
Figure 2. Expression of a dominant-negative VCP mu-
tant induces juxtanuclear accumulation of Bap31 and
the retrotranslocation machinery. (A) A dominant-neg-
ative FLAG-VCP mutant (K524M) or FLAG-VCP WT
was expressed in COS-7 cells, and the cells were stained
for the indicated proteins. The boxed areas are enlarged
in the insets. Bars, 5 m. (B) Lysates of 293T cells ex-
pressing FLAG-VCP K524M or FLAG-VCP WT with
HA-Bap31 (left) or HA-reticulon 3 (RTN3) (right) were
subjected to immunoprecipitation with anti-FLAG, and
then they were immunoblotted with the indicated anti-
bodies. The star denotes immunoglobulin light chain.
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mutant (bottom row). Derlin-1 seems to be part of a retro-
translocation channel that is associated with both the polyu-
biquitination machinery and the VCP complex containing
VCP-interacting membrane protein (Ye et al., 2003, 2004,
2005; Lilley and Ploegh, 2004). The presence of Derlin-1 in
the quality control compartment suggests that this compart-
ment represents the site for retrotranslocation of ERAD sub-
strates from the ER. In contrast to Derlin-1, Sec61, a subunit
of the Sec61 translocon that was originally assumed to be a
channel for ERAD substrates (Wiertz et al., 1996), did not
markedly accumulate at the juxtanuclear region (Figure 2,
fifth row).
To explore the possible link between Bap31 and VCP in
quality control compartments, FLAG-VCP WT or FLAG-
VCP K524M was coexpressed with HA-tagged Bap31, and
then it was immunoprecipitated using anti-FLAG. As shown
in Figure 2B, Bap31 was coprecipitated with the VCP mutant
(lane 4), but not with the wild-type protein (lane 3). A
control ER protein, reticulon 3 was not coprecipitated with
VCP WT (lane 7) or the mutant (lane 8). These results may
suggest that Bap31 interacts with VCP in quality control
compartments.
Bap31 Accumulates at the Juxtanuclear Region by
H89 Treatment
Which feature of Bap31 allows it to accumulate at the jux-
tanuclear region of cells when ERAD is inhibited? Given that
the formation of the ER quality control compartment con-
taining Bap31 at the juxtanuclear region is dependent on
microtubules (Figure 1D), one possibility is that Bap31 in
normal cells may move within the ER or between the pe-
ripheral ER and a juxtanuclear ER-related compartment in a
microtubule-dependent manner. To explore this possibility,
we investigated whether chemicals that perturb microtu-
bule-dependent membrane transport from the ER affect
Bap31 localization. H89 blocks protein export out of the ER
(Jamora et al., 1999) perhaps by mildly inhibiting the binding
of COPII proteins to ER exit sites (Aridor and Balch, 2000;
Lee and Linstedt, 2000), where COPII-coated vesicles in-
volved in ER-to-Golgi transport are formed (Gurkan et al.,
2006). It also blocks Golgi disassembly occurring during
mitosis, likely by keeping Arf1, a small GTPase that regu-
lates the recruitment of COPI to membranes (Lippincott-
Schwartz and Liu, 2006), in an active state (Altan-Bonnet
et al., 2003). We found that H89 induces a rapid (within 15
min) and reversible accumulation of Bap31 at the jux-
tanuclear region (Figure 3A, top row). Although the region
where Bap31 accumulated was very close to the Golgi ap-
paratus, represented by the KDEL receptor ERD2, at the
level of light microscopy (Figure 3A, middle row), immuno-
electron microscopic analysis showed that accumulated
Bap31 is not localized at the Golgi apparatus, but in an area
of the ER or ER-related compartment close to the centrosome
(Figure 3B). The effect of H89 on Bap31 is specific because
H89 had no effect on the localization of BiP and SERCA2
(Figure 3A, bottom row) and other ER proteins (data not
shown). The H89-induced accumulation of Bap31 at the
juxtanuclear region was blocked by Noc (Figure 3C, top row)
or overexpression of dynamitin (bottom row), indicating the
involvement of microtubules in this transport process.
To investigate the correlation between H89 activity on
Bap31 redistribution and COPII localization, we performed
a titration experiment. As shown in Supplemental Figure S1,
H89, at concentrations up to 75 M, did not induce marked
change in the distribution of Sec31A, a COPII subunit, or
-COP, a COPI subunit (Bonifacino and Glick, 2004; Lee
et al., 2004), whereas Bap31 redistribution occurred in many
cells upon incubation with H89 at a concentration as low as
50 M. At 100 M H89, some background staining was seen
for Sec31A, which may reflect dissociation of COPII from
membranes. We could not test H89 at concentrations higher
than 100 M because COS-7 cells were detached from cov-
erslips, even those coated with poly-l-lysine. It seemed that
the effect of H89 on COPII localization is weaker in COS-7
cells than HeLa cells (Lee and Linstedt, 2000; Puri and
Linstedt, 2003; Jiang et al., 2006).
Next, we examined whether Bap31, upon H89 treatment,
moves to the juxtanuclear region through ER exit sites, as in
the case of secretory cargos. To this end, cells were incubated
with Noc to depolymerize microtubules. In Noc-treated
cells, cargo proteins that are transported through the con-
ventional pathway can exit the peripheral ER and accumu-
late at ER exit sites. Simultaneously, proteins in the ERGIC
and the Golgi apparatus are redistributed to ER exit sites
(Cole et al., 1996; Storrie et al., 1998; Hammond and Glick,
2000). As shown in Supplemental Figure S2, in Noc-treated
cells, Bap31 did not accumulate at ER exit sites defined by
Sec31A (third row), but remained within the ER where
SERCA2 was present (second row) upon H89 treatment. H89
treatment did not affect the exit site localization of -COP
(fourth row) or a Golgi marker, GM130 (Nakamura et al.,
1995) (bottom row), in Noc-treated cells. These results sup-
Figure 3. Bap31 moves to the juxtanuclear region along the micro-
tubule track by H89 treatment. (A) COS-7 cells were incubated with
50 M H89 for 15 min, and then they were stained for Bap31 (top
left), BiP, or SERCA2 (bottom row). The middle row shows enlarged
images of the boxed area double stained for Bap31 and ERD2. To
demonstrate the reversibility of the effect of H89, H89-treated cells
were incubated for 3 h without H89 and stained for Bap31 (top
right). Bars, 5 m. (B) Electron microscopic analysis of H89-treated
COS-7 cells. Gold-enhanced immunogold-labeled Bap31 is located
close to the centrosome (arrowhead), but not in the Golgi apparatus
(arrows). Bar, 500 nm. (C) Preincubation of COS-7 cells with 5
g/ml Noc for 3 h (top row) or overexpression of FLAG-dynamitin
(bottom row) blocks H89-induced juxtanuclear accumulation of
Bap31. Arrows indicate cells expressing FLAG-dynamitin. Bars, 10
m.
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port the idea that the transport of Bap31 occurs not through
the conventional transport pathway.
Bap31 and Derlin-1 Accumulate at the Juxtanuclear
Region in Active Arf1-expressing Cells
To further characterize H89-induced Bap31 movement to the
juxtanuclear region, we overexpressed the constitutively ac-
tive and inactive forms of Sar1p and Arf1, which are small
guanosine triphosphatases (GTPases) responsible for the
formation of COPII- and COPI-coated vesicles, respectively
(Bonifacino and Glick, 2004; Lee et al., 2004). Expression of
these mutants in cells block ER–Golgi transport at specific
stages in conventional transport processes (Ward et al., 2001;
Altan-Bonnet et al., 2003).
When inactive Sar1p (Sar1p[T39N]) or the active form
(Sar1p[H79G]) was expressed in COS-7 cells, H89-induced
juxtanuclear accumulation of Bap31 was blocked (Figure
4A). In contrast, when the active form of Arf1 (Arf1[Q71L]-
GFP) was expressed, Bap31 accumulated at the juxtanuclear
region without H89 treatment, and it was substantially co-
localized with Arf1[Q71L]-GFP (Figure 4B, top row). Triple
staining revealed that some Arf1[Q71L]-GFP-, Bap31-posi-
tive structures are negative for the Golgi marker ERD2 (Figure
4B, bottom row, arrowheads). Similarly, some Arf1[Q71L]-
GFP-, Bap31-mRFP-positive structures were negative for the
ERGIC marker ERGIC-53 (Figure 4C). These results may
imply that Arf1 binds not only to ERGIC and Golgi mem-
branes but also to ER membranes to some extent.
To assess whether active-Arf1-induced juxtanuclear Bap31
accumulation is related to the quality control compartment, we
compared the localization of Bap31 with that of the putative
retrotranslocation channel Derlin-1. As shown in Figure 4D,
Derlin-1 and Bap31 accumulated at the juxtanuclear region and
substantially colocalized with expressed Arf1[Q71L]-GFP (top
two rows) and Arf1[Q71L]-mRFP (bottom row). Obviously, the
tags did not significantly affect redistribution of Bap31 and
Derlin-1 induced by Arf1[Q71L].
Bap31 Movement and Golgi Reassembly Occur
Independently during Recovery from BFA Treatment
We next tested the effect of BFA on the localization of Bap31.
Contrary to H89 (Altan-Bonnet et al., 2003), BFA prevents the
activation of Arf1, which leads to Golgi disassembly and
redistribution of Golgi components to the ER (Lippincott-
Schwartz and Liu, 2006). BFA treatment had no apparent
effect on Bap31 localization, but during recovery from BFA
treatment, Bap31 was found to move to the juxtanuclear
region and then back to the peripheral region (Figure 5A, left
column). No such marked redistribution took place for other
ER proteins (Figure 5C). Because Golgi reassembly occurs
after BFA washout, we followed the time courses of Bap31
movement and reassembly of the Golgi apparatus. As a
Figure 4. Effects of Sar1p and Arf1 mutants on the localization of Bap31. (A) COS-7 cells expressing mRFP, as a control, or the indicated
FLAG-Sar1p constructs were subjected to H89 treatment, and then they were double stained for FLAG and Bap31. Arrows indicate cells
expressing mRFP or the FLAG-Sar1p constructs. (B) Arf1[Q71L]-GFP–expressing COS-7 cells were stained for Bap31 alone (top row) or for
both Bap31 and ERD2 (bottom row). The boxed areas are enlarged in the insets. Arrowheads indicate the structures where Bap31 is
colocalized with Arf1[Q71L]-GFP, but not with ERD2. N denotes the nucleus. (C) Tet-on HeLa cells expressing both Bap31-mRFP (top right)
and Arf1[Q71L]-GFP (top left) were stained for ERGIC-53 (bottom left). N, nucleus. (D) COS-7 cells expressing Arf1[Q71L]-GFP (top two
rows) and Arf1[Q71L]-mRFP (bottom row) were double stained for Bap31 and Derlin-1. The middle row shows enlarged images of the boxed
areas in the top row. Bars, 10 m.
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Golgi marker, we first used -COP because it exhibited an
entirely diffuse pattern upon BFA treatment and accumu-
lated at a juxtanuclear region much earlier than Golgi en-
zymes, such as mannosidase II, after BFA washout (data not
shown). As shown in Figure 5, A and B, juxtanuclear accu-
mulation of Bap31 preceded -COP reassembly. Next, we
compared the distribution of GM130 with that of Bap31
during recovery from BFA treatment. GM130 is one of the
fast-moving proteins during BFA recovery (Jiang et al.,
2006). As reported previously (Nakamura et al., 1995; See-
mann et al., 2000; Ward et al., 2001), GM130 was distributed
in punctate structures in BFA-treated cells (Supplemental
Figure S3, second row). Although previous studies showed
that combined treatment of normal rat kidney or HeLa cells
with BFA followed by BFA plus H89 causes ER localization
of GM130 (Puri and Linstedt, 2003; Jiang et al., 2006), such
redistribution was not observed in COS-7 cells when 50 M
H89 in addition to 10 M BFA was used (data not shown).
This is perhaps due to a relatively weak action of H89 on
COS-7 cells, as described above. At 60 min after BFA wash-
out, the time when Bap31 accumulated at the juxtanuclear
region in most cells, GM130 accumulated and clustered at
the juxtanuclear region, but it did not exhibit a compact,
ribbon-like pattern (Supplemental Figure S3, fourth row). A
compact Golgi pattern was observed in many cells at 120
min or later after BFA washout. At these time points, Bap31
exhibited a diffuse pattern in many cells due to recycling to
the peripheral ER. The time course of GM130 reassembly
seemed similar to that observed for -COP (Figure 5, A and
B). These results suggest that Bap31 movement and Golgi
reassembly occur independently.
To analyze the movement of Bap31 during recovery from
BFA treatment in living cells, we constructed a plasmid
encoding Bap31-mRFP. Bap31-mRFP and the Golgi marker
NAGFP were transiently expressed in Tet-on HeLa cells,
and their behavior was compared during BFA recovery
using live cell imaging. The data show that the two proteins
independently move to the juxtanuclear region (Supplemen-
tal Figure S4 and Supplemental Movie S1).
Comparison of the Behaviors of Bap31 and ERGIC-53
during Recovery from BFA Treatment
ERGIC-53 cycles principally between the ERGIC and the ER
(Appenzeller-Herzog and Hauri, 2006). Because the behav-
ior of Bap31 during recovery from BFA treatment seemed
similar to that of ERGIC-53, we compared the behaviors of
the two proteins in detail. As described above, because our
anti-ERGIC-53 antibody does not recognize simian ERGIC-
53, we used HeLa cells. In HeLa cells, Bap31 cycled between
the juxtanuclear and peripheral regions more slowly com-
pared with COS-7 cells; the ratio of HeLa cells with jux-
tanuclear Bap31 accumulation to total cells was maximum at
120 min after BFA washout (Supplemental Figure S5). As
shown previously (Nakamura et al., 1995; Ward et al., 2001)
and in this study (Figure 1E), BFA treatment caused some
dispersion of ERGIC-53–positive clusters at the juxtanuclear
region without changing punctate ERGIC-53 staining at the
peripheral region. When BFA was washed out, ERGIC-53
seemed to become concentrated at the juxtanuclear region
(Supplemental Figure S6). At 120–180 min after BFA wash-
out, extensive tubular structures were emitted from cen-
trally concentrated ERGIC-53–positive clusters. Perhaps,
these tubules represent ERGIC-53 in the process of recycling
back to the ER, as seen in the process of recovery from low
temperature treatment (Klumperman et al., 1998). Impor-
tantly, Bap31 was not included in ERGIC-53–positive tubu-
lar structures.
Expression of Bap31 Induces Comigration of ER Proteins
The time course of the redistribution of transiently ex-
pressed Bap31-mRFP after BFA washout seemed to be con-
siderably faster than that of endogenous Bap31. To minimize
the effect of overexpression, Tet-on HeLa cells stably ex-
pressing Bap31-mRFP were established. As shown in Sup-
plemental Figures S5, stably expressed Bap31-mRFP be-
haved quite similarly to the endogenous protein during
recovery from BFA treatment.
Interestingly, some ER proteins, such as SERCA2 (Figure
6, top and second rows), BiP (third row), and calnexin
Figure 5. Bap31 cycles between the cell pe-
riphery and the juxtanuclear region during
recovery from BFA treatment. (A) COS-7 cells
were incubated with 10 M BFA for 30 min,
and then they were washed to remove BFA.
Change in the localization of Bap31 (left col-
umn) and -COP (right column). (B) Quanti-
tation of cells with the juxtanuclear accumu-
lation of Bap31 and -COP. (C) Distributions
of BiP, calnexin, SERCA2, and prolyl-4-
hydroxylase -subunit (PH) at 60 min after
BFA washout. Bars, 10 m.
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(fourth row), comigrated with Bap31-mRFP to the jux-
tanuclear region during recovery from BFA treatment. This
is likely not due to the nonspecific aggregation of proteins
because stably expressed Bap31-mRFP exhibited a reticular
ER pattern and behaved similarly to endogenous Bap31.
Similar comigration was observed for FLAG-tagged Bap31
(data not shown), ruling out the trivial possibility that the
ER proteins comigrate with Bap31-mRFP by binding to the
mRFP moiety. Given that Bap31 interacts with transmem-
brane proteins through mutual TMDs (Adachi et al., 1996;
Annaert et al., 1997; Spiliotis et al., 2000; Ladasky et al., 2006;
Szczesna-Skorupa and Kemper, 2006), it is tempting to spec-
ulate that expression of Bap31 may shift the Bap31/interact-
ing proteins equilibrium toward complex formation, leading
to comigration of Bap31 and its interacting proteins. It
should be noted that juxtanuclear Bap31-mRFP–positive
structures could be stained with an ER/mitochondria-stain-
ing probe, 3,3-dihexyloxacarbocyanine iodide [DiOC6(3)]
(Figure 6, fifth row), confirming that Bap31-mRFP at the
juxtanuclear region is associated with ER or ER-related
membranes. Colocalization of Bap31-mRFP with an ERGIC
marker, ERGIC-53 (sixth row), or a Golgi marker, GM130
(bottom row), was not conspicuous compared with ER
proteins.
TMD2 Is Responsible for Bap31 Recycling from the
Juxtanuclear Region
To gain insight into the mechanism underlying Bap31 cy-
cling, we determined the regions of Bap31 responsible for
cycling. Bap31 possesses three putative TMDs (TMD1-3) and
short N-terminal and long C-terminal cytoplasmic tails with
a C-terminal dilysine motif (Figure 7A). The Bap31 homo-
logue Bap29 shares 47% amino acid identity with Bap31 and
possesses essentially the same hydropathy profile. Never-
theless, Bap29-mRFP was found not to efficiently cycle be-
tween the peripheral and juxtanuclear regions (Table 1A).
We therefore constructed chimeras in which the N-terminal
or C-terminal region of Bap31 was replaced with the corre-
sponding region of Bap29 to determine the domains required
for cycling (Figure 7A). We reasoned if domains responsible
for recycling from the juxtanuclear region are replaced, the
resultant mutants must show juxtanuclear localization with-
out BFA/washout treatment. In contrast, if domains that
participate in the movement to the juxtanuclear region are
replaced, the resultant mutants would not change their lo-
calization during recovery from BFA treatment. The results
of chimera analysis are shown in Supplemental Figure S7
and Table 1B. When regions comprising TMD2 were replaced
by the corresponding Bap29 regions, the resultant chimeras
[29(65)31-mRFP and 29(101)31-mRFP] showed a juxtanuclear dis-
tribution without BFA/washout treatment (Supplemental
Figure S7, third and fourth rows and Table 1B, untreated),
although some dot-like structures were occasionally ob-
served around the juxtanuclear region. These chimeras ac-
cumulated at the juxtanuclear region were dispersed by Noc
or overexpression of dynamitin (data not shown), suggest-
ing that their distribution is dependent on active transport
along microtubules. In contrast, 29(43)31-mRFP, which pos-
sesses a Bap29 region encompassing from the N-terminal tail
to the cytoplasmic loop between TMD1 and TMD2, dis-
played a reticular distribution. These results suggest that
TMD2 is required for recycling from the juxtanuclear region
to the cell periphery.
To verify that juxtanuclear 29(65)31-mRFP–positive struc-
tures are associated with ER membranes, but not with Golgi
membranes, we performed fluorescence loss in photobleach-
ing experiments. To this end, the plasmid for 29(65)31-mRFP
was transfected into cells stably expressing cytochrome b5
fused with GFP (GFP-CB5). When 29(65)31-mRFP was ex-
pressed, GFP-CB5 (Figure 7B, bottom row), as well as en-
dogenous SERCA2 (top row), displayed a juxtanuclear ac-
centuation, in addition to a reticular distribution. The
Figure 6. Expression of Bap31-mRFP induces comigration of ER
proteins to the juxtanuclear region during recovery from BFA treat-
ment. At 120 min after BFA washout, Tet-on HeLa cells stably
expressing Bap31-mRFP were fixed and stained for SERCA2, BiP,
calnexin, ERGIC-53, or GM130, or labeled with DiOC6(3). The sec-
ond row shows enlarged images of the boxed areas in the top row.
N, nucleus. Bars, 10 m.
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repeated bleaching of a peripheral area of a 29(65)31-mRFP–
expressing cell resulted in a marked decrease in the intensity
of juxtanuclear fluorescence derived from GFP-CB5 (Figure
7C, top row). In contrast, no decrease in the intensity of
juxtanuclear fluorescence derived from Golgi-localized GFP-
galactosyltransferase was observed in an experiment using a
similar protocol (Figure 7C, bottom row). These results are
consistent with the idea that the juxtanuclear 29(65)31-
mRFP–positive structures are continuous with ER or ER-
related membranes.
To show that 29(65)31-mRFP is not localized in an inter-
mediate compartment containing ERGIC-53, we performed
two experiments. First, we treated 29(65)31-mRFP–express-
ing HeLa cells with BFA. As shown in Figure 7D, jux-
tanuclear 29(65)31-mRFP was not dispersed by BFA treat-
ment, whereas the dispersion of the ERGIC (ERGIC-53)
(second row) and the Golgi apparatus (GM130) (bottom
row) occurred. Next, we examined whether the distribution
of 29(65)31-mRFP is changed at 15°C, as seen for ERGIC-53
(Klumperman et al., 1998). On incubation of 29(65)31-mRFP-
expressing HeLa cells at 15°C for 2 h, ERGIC-53 was redis-
tributed to larger punctate structures, whereas the distribution
Table 1. Quantitation of cells with juxtanuclear accumulation of
Bap31, Bap29, and chimeras
Construct Untreated
BFA washout
120 min
BFA washout
360 min
A
Bap31-mRFP 2% 72% 10%
Bap29-mRFP 3 16 4
B
29(30)31-mRFP 0% 71.3  7.6% 2.7  3.1%
29(43)31-mRFP 0.7  1.2 33.3  3.1 0.7  1.2
29(65)31-mRFP 89.3  5.0 98.7  2.3 94.7  1.2
29(101)31-mRFP 91.3  3.1 96.0  3.5 92.7  1.2
29(126)31-mRFP 1.3  2.3 19.3  4.2 8.7  2.3
31(125)29-mRFP 0.7  1.2 54.0  8.7 3.3  3.1
In each experiment, 50 cells expressing mRFP-fused chimeric pro-
teins were analyzed. The average values of the three independent
experiments are shown. In A, 200 cells expressing mRFP-fused
proteins were analyzed.
Figure 7. Juxtanuclear structures of a Bap31 mutant are associated with the ER. (A) Schematic representation of Bap31 WT and chimeras
in which the N- or C-terminal region of Bap31 is replaced with corresponding region of Bap29. (B) At 3 h after transfection of the plasmid
for 29(65)31-mRFP, parental Tet-on HeLa cells (top row) or those stably expressing GFP-CB5 (bottom row) were incubated with 1 g/ml
doxycycline for 40 h. The cells were stained for SERCA2 (top row). The boxed areas are enlarged in the insets. (C) Fluorescence loss in
photobleaching. The boxed areas were bleached as described in Materials and Methods. Fluorescence of GFP-CB5 cells (top row) and
GFP-galactosyltransferase (GFP-GT) (bottom row). Arrow indicates a cell expressing 29(65)31-mRFP. N denotes the nucleus. Time is
indicated in minutes:seconds. (D) Tet-on HeLa cells expressing 29(65)31-mRFP were incubated in the absence (top and third rows) or presence
(second and bottom rows) of 10 M BFA for 30 min. Bars, 10 m.
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of 29(65)31-mRFP was not significantly changed (Supplemen-
tal Figure S8).
TMD3 Is Important for the Movement of Bap31 to the
Juxtanuclear Region
To determine the domains responsible for the movement to
the juxtanuclear region, chimera-expressing cells were sub-
jected to BFA/washout treatment. Although a chimera
[29(126)31-mRFP], like wild-type Bap31-mRFP, exhibited a
reticular pattern, it did not efficiently move to the jux-
tanuclear region during recovery from BFA treatment (Sup-
plemental Figure S7, fifth row; and Table 1B, BFA washout
120 min), suggesting that TMD3 is a principal determinant
for the movement to the juxtanuclear region. However, we
do not exclude the possibility that other regions may con-
tribute to this movement. For example, 29(43)31-mRFP
moved less efficiently to the juxtanuclear region compared
with 29(30)31-mRFP (Table 1B). This result may suggest
some contribution of the cytoplasmic loop between TMD1
and TMD2 for the movement to the juxtanuclear region.
In accordance with the view that the TMDs of Bap31 are
responsible for Bap31 cycling, 31(125)29-mRFP in which the
C-terminal long cytoplasmic tail of Bap31 was replaced with
that of Bap29 and a mutant lacking the C-terminal cytoplas-
mic domain including a dilysine motif efficiently cycled
between the periphery and the juxtanuclear region during
recovery from BFA treatment (Supplemental Figure S7 and
Table 1B; and data not shown). It should be noted the
di-lysine motif of Bap31 is not required for Bap31 cycling.
DISCUSSION
Bap31 is a putative cargo receptor for ER export of several
transmembrane proteins (Ladasky et al., 2006, and references
therein). In the present study, we disclosed two important
features of Bap31. One is that Bap31 is a component of the
ER quality control compartment, and the other is that Bap31
cycles between the peripheral ER and a juxtanuclear ER or
ER-associated compartment distinct from the conventional
ER–Golgi intermediate compartment in a microtubule-
dependent manner.
Bap31 Is a Component of the ER Quality Control
Compartment
Several previous studies reported the presence of ER quality
control compartments in mammals (Kamhi-Nesher et al.,
2001; Spiliotis et al., 2002) and yeast (Kiser et al., 2001; Zhang
et al., 2001; Huyer et al., 2004). Although detection of the
mammalian ER quality control compartment in previous
studies was principally dependent on the use of proteasome
inhibitors (Kamhi-Nesher et al., 2001; Spiliotis et al., 2002),
our present results showed that the ATPase-defective VCP
mutant is also usable for this purpose. Furthermore, our
results obtained using the VCP mutant unequivocally dem-
onstrated that the formation of discernible juxtanuclear
quality control compartments is due to inhibition of ERAD.
In cells where proteasomal activity is inhibited and those
where retrotranslocation is blocked, Bap31 accumulates in
the juxtanuclear quality control compartment, implying that
Bap31, which is not an ERAD substrate, is a component of
this compartment. In addition to Bap31, we identified an-
other component of the quality control compartment, i.e.,
Derlin-1. Because Derlin-1 seemingly constitutes a retro-
translocation channel (Lilley and Ploegh, 2004; Ye et al., 2004,
2005), it is likely that the quality control compartment rep-
resents the site from which retrotranslocation substrates exit
the ER into the cytosol. Although our results suggest that
Sec61, a subunit of the Sec61 translocon that was originally
assumed to be a retrotranslocation channel (Wiertz et al.,
1996), is not a bona fide component of the quality control
compartment, it may be incorporated into this compartment
through the interaction with ERAD substrates. Indeed,
Kamhi-Nesher et al. (2001) reported when human asialogly-
coprotein receptor H2a, an ERAD substrate that binds
Sec61, is ectopically expressed, Sec61 is observed in the
quality control compartment.
Cycling of Bap31 between the Peripheral ER and a
Juxtanuclear ER or ER-related Compartment
Although initial evidence for Bap31 cycling was obtained by
using chemicals (H89 and BFA) that perturb cycling, two
lines of evidence suggest that this cycling occurs under
normal conditions. First, expression of the constitutively
active Arf1 caused the accumulation of Bap31 at the jux-
tanuclear region. Second, some Bap31/Bap29 chimeras lo-
calize to the juxtanuclear region in a microtubule-dependent
manner without any artificial treatment. Why Bap31 cycling
has not been discovered? Presumably, mixed movement of
Bap31, i.e., microtubule-dependent cycling and lateral diffu-
sion, has hampered the identification of this cycling path-
way. Obviously, the rate of lateral diffusion is faster than
that of Bap31 cycling. Therefore, use of chemicals that per-
turb Bap31 cycling might be inevitable for us to notice this
novel cycling pathway.
Several lines of evidence clearly indicate that the jux-
tanuclear area where Bap31 accumulates is not the Golgi
apparatus or an intermediate compartment containing
ERGIC-53. First, at the electron microscopic level, Bap31 was
not observed in the Golgi apparatus (Figure 3B). Second,
during BFA recovery Bap31 movement to the juxtanuclear
region preceded Golgi reassembly (Figure 5) and Bap31 was
not included in ERGIC-53–positive tubules (Supplemental
Figure S6). Third, Bap31-mRFP–posivie structures could be
stained with an ER probe, DiOC6(3) (Figure 6). Fourth, jux-
tanuclear fluorescence of GFP-CB5 in 29(65)31-mRFP-
expressing cells decreased by repeated bleaching of a pe-
ripheral area (Figure 7C). Last, in contrast to the sensitivity
of the ERGIC to BFA and low temperature treatment, the
distribution of juxtanuclear 29(65)31-mRFP was not changed
by either treatment (Figure 7D and Supplemental Figure S8).
Although we prefer the idea that the juxtanuclear area
where Bap31 accumulates represents the ER, our data do not
exclude the possibility that the Bap31-accumulated area is a
recycling compartment that does not contain ERGIC-53. If
this possibility is correct, Bap31 cycling between the ER and
the recycling compartment is expected to occur by a novel
nonvesicular mechanism that may be dependent on COPII
and COPI. Our results also do not exclude the possibility
that some Bap31 is transported to the ERGIC and/or the
Golgi apparatus in certain cells, as reported previously (Bell
et al., 2001). It is possible that some Bap31 escapes the cycling
pathway and that it is incorporated into transport vesicles
destined for the Golgi apparatus in some cells and/or under
certain circumstances.
It is obvious that Bap31 cycling is intimately related with
Arf1 function. H89 and BFA, both of which affect Bap31
cycling, are known to keep Arf1 in active and inactive states,
respectively (Altan-Bonnet et al., 2003; Lippincott-Schwartz
and Liu, 2006). Removal of BFA may rapidly and transiently
increase the proportion of active Arf1 species and thereby
induce discernible one round of Bap31 cycling. Expression
of the constitutively active Arf1 resulted in the juxtanuclear
accumulation of Bap31 (Figure 4, B and C). Importantly, the
constitutively active Arf1 also induced the putative ER ret-
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rotranslocation channel Derlin-1 to redistribute to the jux-
tanuclear region (Figure 4D). This finding provides evidence
for a link between the ER quality control compartment and
protein cycling within the ER or ER-related compartments. It
is possible that the vesicular transport machinery, indepen-
dent of its membrane traffic function, plays a role in ERAD
in mammalian cells, as reported in yeast cells (Fu and Sztul,
2003).
Possible Implication for Bap31 Cycling
Based on the present and other data with the assumption
that Bap31 cycles within the ER, we can envisage the fol-
lowing model for the destiny of transmembrane proteins
prone to ERAD (ERAD substrates) in the context of Bap31,
although this model should be verified in future studies. As
a cargo receptor, Bap31 moves within the ER with ERAD
substrates, such as CFTR and class I MHC molecules. Bap31
may function to provide a milieu for efficient folding by
recruiting some ER proteins including chaperons (Figure 6).
Ladasky et al. (2006) recently reported that overexpression of
Bap31 increases the cell surface level of class I MHC mole-
cules, whereas Bap29 overexpression rather inhibits class I
MHC molecule transport. This result may be relevant to the
fact that Bap31 cycles between the juxtanuclear and periph-
eral regions, whereas Bap29 does not. If the folding of ERAD
substrates takes place with the help of ER chaperones, the
folded proteins may dissociate from Bap31 and be incorpo-
rated into COPII vesicles at peripheral ER exit sites (Ellgaard
and Helenius, 2003). Perhaps because it takes some time for
inefficiently folding proteins to be matured, they may move
with Bap31 in a dynein–dynactin-dependent manner from
the peripheral ER to the juxtanuclear region where ER exit
sites are concentrated (Gurkan et al., 2006). When folding
occurs, ERAD substrates exit the ER from the juxtanuclear
exit sites. The vicinity of juxtanuclear ER exit sites to the
Golgi apparatus may shorten the time required for ER-to-
Golgi transport. When ERAD substrates do not fold cor-
rectly until Bap31–ERAD substrates reach quality control
compartments at the juxtanuclear region, they may be ret-
rotranslocated, ubiquitinated, and degraded by the protea-
somal machinery that concentrates at the juxtanuclear re-
gion (Wigley et al., 1999), or deposited as aggresomes
observed at the juxtanuclear region when misfolded pro-
teins accumulate beyond the capacity of proteasomal activ-
ity (Johnston et al., 1998). Bap31, not an ERAD substrate,
dissociates from immature proteins and recycles from qual-
ity control compartments back to the peripheral region. The
inhibition of retrotranslocation by a dominant-negative VCP
mutant may cause congestion of the retrotranslocation chan-
nel with Bap31–ERAD substrates, leading to some associa-
tion of Bap31 with the VCP mutant, which was detectable by
immunoprecipitation (Figure 2B). The fact that Bap31 accu-
mulates at the juxtanuclear region in some COS-7 cells under
basal conditions (Figure 1A) may reflect a high level of pro-
duction of ERAD substrates that have occurred accidentally.
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